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havior and menstrual symptoms dimensions were excluded
because of conceptual issues. In the future, they will be
presented as optional modules. The analyses identified a
new structural model applicable to pre, peri and post-
menopausal women. The new WHQ is made of a 23-
item core questionnaire which investigates 6 domains:
anxiety/depressed mood, well-being, somatic symptoms,
memory/concentration, vasomotor symptoms, and sleep
problems. The cross-sectional psychometric properties of
the 23-item WHQ in each country were good and found
to be better than those obtained using the 37-item ver-
sion. CONCLUSIONS: At this stage, the 23-item WHQ
can be used in international trials to assess the impact of
condition, disease or treatment on emotional and physi-
cal well-being of women. Its reproducibility and respon-
siveness to change over time need to be documented.
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In a large Phase III double-blind randomised clinical trial,
the CAPRIE study (clopidogrel versus aspirin in Patients
at Risk of Ischemic Events), two anti-platelet agents were
compared in secondary prevention of ischemic events
(myocardial infarction, ischemic stroke, vascular death)
in atherothrombotic patients. The study was not de-
signed to collect health economic parameters. OBJEC-
TIVES: we needed to assess the incremental cost-effec-
tiveness ratio of the new anti-platelet agent in the main
European countries and to test various hypotheses.
METHODS: Clinical outcomes: A Markov model de-
signed with several clinical states combined the rates of
all ischemic events (fatal and non fatal, primary and sub-
sequent) reported in the CAPRIE study. The rates of ad-
verse events were also taken into account. Survival data:
the remaining life expectancy of the patients who experi-
enced an event was not directly estimated from the CAP-
RIE study as the mean follow-up of the patients was only
two years. The survival estimates was approached by
identifying, in the Framingham study, cohorts of patients
similar to the CAPRIE patients. Resources use and costs:
decision trees about inpatient and outpatient manage-
ment of myocardial infarctions and ischemic strokes were
built from available data (literature, data base, expert
opinion) and were locally validated. RESULTS: The eco-
nomic model allowed to calculate the incremental cost-
effectiveness ratio of the new anti-platelet agent for the
basic scenario (CAPRIE study) and for other scenarios
(changes of the time horizon, considering that the com-
parator could not be the reference treatment for all the
patients in a real life situation, high risk patients analy-
sis). CONCLUSION: Because they are protocol driven,
the Phase III double-blind randomised clinical trials do
not usually reflect what would happen in the real life.
Modeling, which allows to perform simulations, could be
a way of correcting.
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BACKGROUND: The development of an economic
model to assess antipsychotics for first episode schizo-
phrenia raised several issues: (i) clinical and economic ev-
idence relates to chronic schizophrenia; (ii) inconsistent
reporting of outcomes and adverse events; (iii) compari-
son of costs and outcomes across several interventions is
complicated by (a) an absence of head to head compari-
sons (b) intolerance or resistance to 3 plus antipsychotics.
OBJECTIVES: To design a decision analytic model to
evaluate the relative efficiency of antipsychotics. METH-
ODS: Two composite variables were defined to incorpo-
rate 23 efficacy and safety events: (i) acceptable treat-
ment (able/willing to continue allocated therapy, with/
without side effects or symptom control) (ii) unaccept-
able treatment (unacceptable side effects or symptom
control, non compliance). Utility values were defined for
each variable. Clinical data were extracted from system-
atic reviews separately for first episode and chronic
schizophrenia. Age specific resource use data were esti-
mated from national statistics to proxy first episode pa-
tients. Follow on therapy for people failing first therapy
was estimated by (i) specifying drug sequence; (ii) treat-
ing follow on therapy as a random event. Monte Carlo
simulation analysis was used to reduce complexity and
incorporate uncertainty. RESULTS: It was not possible
to identify consistent data for first episode patients only.
Interpretation of the specific treatment sequences was
complex with 32 possible combinations identified. There
were substantial differences within classes of antipsychot-
ics. The results were sensitive to: (i) specification of fol-
low on therapy (ii) distributional form applied to data.
CONCLUSIONS: The analysis highlighted the poor
quality and absence of relevant data. This could not be
dealt with by modelling. Current classifications of typical
and atypical antipsychotics may not be relevant.
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